Showing 1781-1790 of 5957 results for "".
- ASRS Announces Virtual Annual Scientific Meeting July 24-26, 2020https://modernod.com/news/asrs-announces-virtual-annual-scientific-meeting-july-24-26-2020/2477759/Due to the COVID-19 pandemic, the American Society of Retina Specialists (ASRS) has decided to hold its annual meeting online. In a letter to membership, Timothy Murray, MD, MBA, ASRS President, and Philip Ferrone, MD, Program Chair, said that the ASRS Board of Directors has concluded that
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Pixium Vision Announces Receipt of € 1.8 Million from the French Government as Research Tax Credithttps://modernod.com/news/pixium-vision-announces-receipt-of-eur-18-million-from-the-french-government-as-research-tax-credit/2481661/Pixium Vision SA announced that it has received a €1.8 million Research Tax Credit from the French government. This cash injection will help extend the company’s cash runway until the end of September 2023, providing more flexibility to pursue its longer-term f
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGDhttps://modernod.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its phase 2 clinical trial in 270 patients with dry eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in
- Holland Foundation for Sight Restoration Launched to Provide Life Changing Eye Surgerieshttps://modernod.com/news/holland-foundation-for-sight-restoration-launched-to-provide-life-changing-eye-surgeries/2479402/Edward Holland, MD, a pioneering ophthalmologist in the treatment of Severe Ocular Surface Disease, today announced the launch of the Holland Foundation for Site Restoration with a goal of establishing Centers of Excellence (COEs) throughout the country that would specialize in site restoration p
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- Katena Products Announces Launch of the New Katena.comhttps://modernod.com/news/katena-products-announces-launch-of-the-new-katena-com/2479878/Katena Products has announced the launch of the new katena.com, an interactive and engaging ecommerce and education portal. The new site enables existing and prospective customers to review the complete assortment of Katena products and immediately order online. The new site integrates all